Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study

Introduction For hemodialysis patients at high risk of bleeding, a regional anticoagulant can be used, such as citrate or nafamostat mesylate (NM). The objective of this study was to evaluate NM as an alternative to citrate for anticoagulation in hemodialysis patients at high risk of bleeding.Method...

Full description

Bibliographic Details
Published in:Renal Failure
Main Authors: Jiangtao Li, Lirui Wang, Yuqiu Lu, Ying Zhou, Yue Chen
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Subjects:
Hemodialysis
anticoagulation
nafamostat mesylate
citrate
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2025.2464830

Internet

https://www.tandfonline.com/doi/10.1080/0886022X.2025.2464830

Similar Items